会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • METHOD OF PREDICTING RESPONSE TO THALIDOMIDE IN MULTIPLE MYELOMA PATIENTS
    • 在多发性甲状腺功能亢进患者中预测对硫代二酯反应的方法
    • US20120214710A1
    • 2012-08-23
    • US13390836
    • 2010-08-17
    • Rajesh RajpalPaul DowlingMartin M. ClynesPeter O'GormanColin Clarke
    • Rajesh RajpalPaul DowlingMartin M. ClynesPeter O'GormanColin Clarke
    • G01N33/574C40B40/10
    • G01N33/57426G01N33/57407G01N2800/52G01N2800/60
    • A method of predicting response to thalidomide, or thalidomide analogs, in an individual with cancer, especially cancers for which thalidomide has been implicated as a treatment, such as Multiple Myeloma (MM) employs one or more of a panel of biomarkers that have been shown to be differentially expressed in cancer patients that respond to thalidomide (hereafter “Responders”) relative to cancer patients that do not respond to thalidomide (hereafter “Non-responders). The method involves assaying a biological sample from the individual to determine the abundance of at least three biomarkers including Vitamin-D binding protein precursor (VDB) (Sequence ID 1) and Serum amyloid A protein (SAA) (Sequence ID 3), and at least one of beta-2-microglobulin (B2M) (Sequence ID 4), Haptoglobin (Hp) precursor (fragment) (Sequence ID 5), and zinc-alpha-2-glycoprotein (ZAG) (Sequence ID 2). Correlation of the abundance value for the at least three biomarkers with a reference abundance value from a Responder or Non-responder enables predication of response to thalidomide for the patient.
    • 预测具有癌症的个体中沙利度胺或沙利度胺类似物的反应的方法,特别是作为治疗的沙利度胺,例如多发性骨髓瘤(MM)的癌症,其使用已经显示的一组或多种生物标志物 相对于不响应沙利度胺的癌症患者(以下简称“无应答者”),对与沙利度胺反应的癌症患者(以下称为“应答者”)进行差异表达。 该方法包括测定来自个体的生物样品以确定包括维生素-D结合蛋白前体(VDB)(序列ID 1)和血清淀粉样蛋白A蛋白(SAA)(序列ID 3))的至少三种生物标志物的丰度,以及 β-2-微球蛋白(B2M)(序列ID4),Haptoglobin(Hp)前体(片段)(序列ID 5)和锌-α-2-糖蛋白(ZAG)中的至少一种(序列ID 2)。 至少三种生物标志物的丰度值与来自应答者或非应答者的参考丰度值的相关性使得能够预测患者对沙利度胺的反应。